Navigation Links
NASDAQ Gives Dynatronics a Third Three-Month Extension for Minimum Bid Price Compliance
Date:3/31/2009

SALT LAKE CITY, March 31 /PRNewswire-FirstCall/ -- Dynatronics Corporation (Nasdaq: DYNT) today announced that NASDAQ has filed a third grace period extension with the SEC, giving the company until approximately September 27, 2009, to comply with NASDAQ's $1 per share minimum bid rule.

"We are pleased that NASDAQ has again extended the timeframe for compliance," stated Kelvyn H. Cullimore Jr., chairman and president of Dynatronics. "This will allow us time to announce our year-end results, which are expected to show significant improvement over the prior year."

Dynatronics recently reported a profit for the quarter ended December 31, 2008, showing substantially improved results for that period. The company also announced it had retained Vici Capital to assist in seeking ways to improve revenues and minimize expenses. Partly as a result of that process, the company has taken steps to reduce annual expenses by approximately $1,000,000. Additional savings are expected to be achieved in subsequent months from this effort.

"In the quarter ending June 30, 2009, we plan to introduce a new, high-margin product to the physical medicine market," Cullimore added. "The combination of new products, reduced expenses and improved revenues is expected to lead to significantly improved operating results and generate sustainable earnings improvements for the company."

Dynatronics manufactures, markets and distributes advanced-technology medical devices, orthopedic soft goods and supplies, treatment tables and rehabilitation equipment for the physical therapy, sports medicine, chiropractic, podiatry, plastic surgery, dermatology and other related medical, cosmetic and aesthetic markets. More information regarding Dynatronics is available at www.dynatronics.com.

This press release contains forward-looking statements. Those statements include references to the company's expectations for future events. Such statements are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements in this press release include the statements concerning anticipated improvements for the quarter ending June 30, 2009, the anticipated impact of the introduction of a new product in the quarter ending June 30, 2009, the expectation that changes implemented with the assistance of Vici Capital will reduce operating expenses by approximately $1,000,000, the expectation that additional savings are expected to be achieved in the coming months, and the statement that these developments are expected to lead to significantly improved operating results and generate sustainable earnings improvements for the company. Actual results may vary from the views expressed in the forward-looking statements contained in this release. The development and sale of the company's products are subject to a number of risks and uncertainties, including, but not limited to, changes in the regulatory environment, competitive factors, inventory risks due to shifts in market demand, market demand for the company's products, availability of financing at cost effective rates, and the risk factors listed from time to time in the company's SEC reports including, but not limited to, the report on Form 10-K for the year ended June 30, 2008.


'/>"/>
SOURCE Dynatronics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. VirtualScopics Receives Further Extension to Regain Compliance With Nasdaq
2. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
3. NASDAQ Panel Grants Extension to DATATRAK for Continued Listing on the NASDAQ Capital Market
4. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
5. Pharmos Corporation Announces Receipt of Nasdaq Delisting Determination
6. The LCA-Vision Full Value Committee Urges LCA-Vision (NASDAQ: LCAV) Stockholders to Reject the Status Quo
7. Pharmacyclics Receives Nasdaq Notification
8. Mylan Vice Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Opening Bell
9. Cell Therapeutics to Resume Trading on MTA and NASDAQ
10. The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders
11. EngagementHealth(R) Launches Comprehensive Wellness Programs With Rurban Financial Corp. (Nasdaq - RBNF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Milwaukee, WI (PRWEB) , ... October 13, 2017 , ... ... movement in medicine known as “patient engagement.” The patient is doing more than filling ... research partners. , “There is an increasing emphasis in health care and research ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... the certification process to promote standards of excellence for the field of eating ... for March 22 – 25, 2018 in Orlando, Florida at the Omni Resort ...
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & Associates ... special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to date ... elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded by ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills ... specialty vendors and unique items from across the nation, this holiday-themed event will raise ... offered by the VNA. The boutique will be open Saturday, November 4 (10:00 ...
(Date:10/13/2017)... ... 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... popular and least understood books in the Holy Scriptures, Revelation. The Book of Revelation ... scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... 11, 2017  BioPharmX Corporation (NYSE MKT: BPMX) researchers ... an innovative way to use nonlinear optical imaging to ... new drugs. ... will show how researchers from BioPharmX and the Wellman ... used a suite of imaging techniques in what is ...
(Date:10/10/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a ... today shared the results of a study highlighting the ... administration of polio vaccines. The study results were presented ... by Dr. Ondrej Mach , Clinical Trials and ... and recently published in the journal Vaccine. i ...
(Date:10/4/2017)... OBP Medical , a leading ... today announced regulatory approval from Brazil,s ... Nacional de Vigilância Sanitária (ANVISA)) to market ... with integrated LED light source and smoke evacuation ... of a tissue pocket or cavity during surgical ...
Breaking Medicine Technology: